Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

DR JESSICA DONINGTON
Dr. Jessica Donington, the chief of thoracic surgery at the University of Chicago, wants to keep mesothelioma patients living not just longer, but better, too.

“When we treat people for cancer, it’s not just to live longer,” begins Dr. Jessica Donington. “It’s longer and better. I don’t want to buy you bad time.”

Donnington, the chief of thoracic surgery at the University of Chicago, specializes in two of the most insidious and aggressive cancers—lung cancer and mesothelioma. Unlike other forms of cancer which can be caught in the early stages—like breast or skin cancer—lung cancer or mesothelioma patients typically receive their diagnoses after they’ve begun presenting late-stage symptoms. Mesothelioma patients in particular face grim odds. According to Asbestos.com, 40 percent of mesothelioma patients survive at least one year. But only 52 percent of peritoneal mesothelioma patients and a mere 12 percent of pleural mesothelioma patients survive five years.

That is why finding effective and harm-reducing treatments is so key in the mesothelioma world. “With meso, I do think the quality of what we give [patients] is so, so important because this is a rough disease,” Donnington says. “It really can impact people quite dramatically.”

The University of Chicago (U of C), unlike other facilities, has embraced a holistic approach to treating the rare and deadly disease. Donington’s team is led by Hedy Lee Kindler, M.D., the medical director of gastrointestinal oncology and director of U of C’s mesothelioma program. “We work under her direction because she’s really brilliant,” Donington says. In addition to Kindler, their program also includes surgeons, radiation oncologists, radiologists, pathologists, nutritionists and palliative care.

Dr. Donington, left

 

Dr. Donington, left

Nearly all patients who come to U of C’s mesothelioma program first see Kindler. Later, patients are assessed to see if surgery is an option. This is where Donington comes in. Donington primarily performs pleurectomy/decortication surgeries for pleural mesothelioma patients, a lung-sparing procedure that removes the pleural lining and other diseased tissues around the lung as well as any visible tumors on the surface of the lung or the remaining chest.

According to Donington, pleurectomy/decortication is a more difficult surgery than the preceding and more common extrapleural pneumonectomy, which removes the lung entirely. “Most of my lung cancer patients go home in about two days; these patients stay more like six days,” Donington says.

But the benefits for the patient are well worth it. While she was at New York University, Donington worked with Dr. Raja Flores, the chairman for the Department of Thoracic Surgery and a professor of Thoracic Surgery at The Mount Sinai Medical Center. Flores and Donington found that patients who had an extrapleural pneumonectomy had an overall poorer recovery than those who had the pleurectomy/decortication. “We didn’t feel like they ever really got all the way back to baseline,” Donington says. “Like they were always a bit hampered by their operation.”

Treating mesothelioma, therefore, requires sobering realism. “The patients are all going to recur. It’s that kind of disease. We cure so few,” Donington adds. But with a pleurectomy/decortication, patients are left much stronger and able to receive more treatment, including radiation and chemotherapy. Pneumonectomy patients—often too weak, frail, short of breath or emaciated—could receive no further treatment, and ultimately died.

Dr. Donington, left, with a patient
Dr. Donington, left, with a patient

“I don’t want to buy you time in the hospital. I don’t want to buy you time on oxygen. I don’t want to buy you time when you can’t enjoy your life, and I think with pneumonectomy, we were doing that,” says Donington. “When we do the pleurectomy/decortication and leave them with two lungs, the time we buy them is better time. Maybe that’s the better message to tell.”

Although surgery has proven to be beneficial to many mesothelioma patients, it is not an option for all meso patients. “I actually think it’s probably an option only for a small percentage of them,” Donington says. Donington prefers to operate on patients with epithelial disease—affecting the epithelial tissues lining the surfaces of our skin, our digestive organs and our respiratory organs—rather than those with sarcomatoid disease.

The mesothelioma should also be fairly low volume. “It’s hard once it’s in the fissures. It’s hard if there’s dense disease,” Donington says. “The hardest thing is if it’s growing into the chest wall or the mediastinum. Those are the kind of things that make people inoperable.” And patients should be fairly young and pretty healthy. “It’s not like we would say no to someone who’s in their 80s, but it’s tough, and someone who’s elderly has significant comorbidities or is frail,” she says.

Steps in the advancement of treatment toward mesothelioma are not as common as other forms of cancer, but Donington remains hopeful that new developments are on the horizon and many of them may develop through the University of Chicago’s unique program. “The steps of meso are all small, but we’re all making them. There’s no doubt about it,” Donington says. “We do have new medicines, we do have more effective treatments. We are better at marrying all of our different treatments together. So that just needs to continue.”

More
articles

MISS NIKKI
(Y)our Stories

The Best Medicine

We celebrate the life and laughter of Miss Nikki, a Chicago-based stand-up comedian who fought and lost her battle with breast cancer.

Read More »
LALBAGH GLASSHOUSE
Complementary Medicine

Stay and Play in … Bengaluru, India

Bengaluru, in the southern Indian state of Karnataka, is a teeming metropolis with a friendly soul, featuring good food, stunning cultural delights, and high-tech hospitals, making it an attractive medical tourism destination.

Read More »
GOURDS
Nutrition

Recipes: Life is Gourd

Allow the flavors of fall to ease you into this season. These anti-inflammatory dishes balance out the sweet, the savory, the acid and the spice and will have your friends and family feeling the love.

Read More »
JOHNNY BENCH
(Y)our Stories

Baseball and Basal Cells

Johnny Bench of the Cincinnati Reds is “on the ball” when it comes to skin cancer. Cancer Wellness talks with Bench about his skin cancer diagnosis and how “an ounce of prevention is worth a pound of cure.”

Read More »
dostarlimab
Colorectal Cancer

Wonder Drug?

A recent clinical trial using an immunotherapeutic “checkpoint inhibitor” completely eradicated colorectal cancer in all 18 participants.

Read More »